Ethics of predictive DNA-testing for hereditary breast and ovarian cancer

Patient Education and Counseling

Volumn 35, Issue 1, 1998, Pages 43-52

  De Wert, Guido ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Ethics; Hereditary breast cancer; Predictive genetic testing; Protocol

Indexed keywords

BREAST CANCER; DNA DETERMINATION; ETHICS; FAMILIAL CANCER; FEMALE; GENE MUTATION; HUMAN; ONCOGENE; OVARY CANCER; PREDICTION; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW;

EID: 0032415738     PISSN: 07383991     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-3991(98)00082-2     Document Type: Article

References (38)

1. Cornelisse C.J., Devilee P. Facts in cancer genetics. Pat Educ Couns. 32:1997;1-7.
2. Birch J.M. Li-Fraumeni Syndrome. Eur J Cancer. 30A(13):1994;1935-1941.
3. WMA proposal on predictive medicine. Bull Med Eth. Nov. 1995, 5-6.
4. Tibben A. What is knowledge but grieving? On psychological effects of presymptomatic DNA-testing for Huntington's disease (thesis). Rotterdam: Erasmus Universiteit, 1993.
5. International Huntington Association and World Federation of Neurology. Guidelines for the molecular genetics predictive test in Huntington's disease. Neurology 1994;44:1533-1536.
6. Li F.P., Garber J.E., Friend S.H. Recommendations on predictive testing for germ line p53 mutaties among cancer prone individuals. J Natl Cancer Inst. 84:1992;1156-1160.
7. de Wert G. Predictief testen op p53-mutaties; ethische overwegingen. (Predictive testing for p53 mutations; ethical considerations). Ned Tijdschr Geneeskd. 140:1995;1350-1353.
8. Weber B. Breast cancer susceptibility genes: current challenges and future promises. Ann Int Med. 124:1996;1088-1090.
9. European Community Huntington's Disease Collaborative Study Group. Ethical and social issues in presymptomatic testing for Huntington's disease: a European community collaborative study. J Med Genet 1993;30:1028-1035.
10. DeGrazia D. The ethical justification for minimal paternalism in the use of the predictive test for Huntington's disease. J Clin Ethics. 2:1991;219-228.
11. Working Party of the Clinical Genetics Society (UK). The genetic testing of children. J Med Genet 1994;31:785-797.
12. Feinberg J. The child's right to an open future. In: Aiken W, LaFollette, eds., Whose child? Children's rights, parental authority, and state power. Totowa, New Jersey: Littlefield Adams, 1980:124-153.
13. Lynch H.T., Lemon S.J., Durham C.et al. A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer. 79:1997;2219-2228.
14. Collins F. Commentary on the ASCO Statement on Genetic Testing for Cancer Susceptibility. J Clin Oncol. 14:1996;1738-1740.
15. Guidelines of a German Ethics Committee (Kommission für ffentlichkeitsarbeit und ethische Fragen der GfH. Stellungnahme zur Entdeckung des Brustkrebsgens BRCA1. Med. Genetik 1/1995, 8-10.
16. de Wert G. Predictive testing for Huntington disease and the right not to know. Some ethical reflections. In: Evers-Kiebooms G, Fryns J-P, Cassiman J-J, van den Berghe H, editors. Psychosocial aspects of genetic counselling. March of Dimes Birth Defects Foundation. Birth Defects: Original Article Series, 1992;28:133-9.
17. Science and Technology Committee. Human genetics: The science and its consequences. Third report, vol 1. London: HMSO, 1995.
18. Tibben A., Stevens M., de Wert G.et al. Preparing for presymptomatic DNA testing for early onset Alzheimer's disease/cerebral haemorrhage and hereditary Pick disease. J Med Genet. 34:1997;63-72.
19. Adam S., Wiggins S., Whyte P.et al. Five year study of prenatal testing for Huntington's disease: demand, attitudes, and psychological assessment. J Med Genet. 30:1993;549-556.
20. Post S. Selective abortion and gene therapy: reflections on human limits. Human Gene Therapy. 2:1991;229-233.
21. Lancaster J.M., Wiseman R.W., Berchuck A. An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene. Obstet Gynecol. 87:1996;306-309.
22. Bloch M., Hayden M.R. Opinion: Predictive testing for Hunting ton disease in childhood: challenges and implications. Am J Hum genet. 46:1990;1-4.
23. Gullick W.J., Handyside A.H. Pre-implantation diagnosis of inherited predisposition to cancer. Eur J Cancer. 30A:1994;2030-2032.
24. de Wert G. Ethics of pre-implantation genetic diagnosis: a Gordian knot. Biomed Ethics. Newsletter of the European Network for Biomedical Ethics. 1:1996;9-14.
25. Council of Europe. Convention for the protection of human rights and dignity of the human being with regard to the application of biology and medicine: Convention on Human Rights and Biomedicine. Strasbourg: Directorate of Legal Affairs, November 1996.
26. Taylor C.A., Myers R.H. Long-term impact of Huntington Disease linkage testing. Am J Med Genet. 70:1997;365-370.
27. Faden RR, Beauchamp TL. A history and theory of informed consent. Oxford: Oxford University Press, 1986.
28. Geller G., Botkin J.R., Green M.J.et al. Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. (Consensus Statement). J Am Med Assoc. 277:1997;1467-1474.
29. Struewing J.P., Hartge P., Wacholder S.et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New Engl J Med. 336:1997;1401-1408.
30. President's Commission, Screening and counselling for genetic conditions. The ethical, social, and legal implications of genetic screening, counselling, and education programs. Washington DC: U.S. GPO, 1983.
31. Adams J. Confidentiality and Huntington's chorea. J Med Ethics. 16:1990;196-199.
32. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 1996;14:1730-6.
33. Burke W., Daly M., Garber J.et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. J Am Med Assoc. 277:1997;997-1003.
34. Meijers-Heijboer EJ, van Geel AN, Klijn JGM, et al. Uptake of presymptomatic DNA-test for BRCA1 and BRCA2 mutations; experiences in Rotterdam from 1994-1996. (abstract of a paper presented at the Fourth international meeting on psychosocial aspects of genetic testing for hereditary breast and/or ovarian cancer, Rotterdam, June 24th, 1997).
35. Kinzler K.W., Vogelstein B. Gatekeepers and caretakers. Nature. 386:1997;761-763.
36. Vaidya J., Baum M. Benefits and risks of screening mammography in women with BRCA1 and BRCA2 mutations (letter). J Am Med Assoc. 278:1997;290.
37. Baird PA. Opportunity and danger: medical, ethical and social implications of early DNA screening for identification of genetic risk of common adult onset disorders. In: Knoppers BM, Laberge CM, editors. Genetic screening. Amsterdam: Excerpta Medica, 1990:279-87.
38. Wexler N. Clairvoyance and caution: repercussions from the Human Genome project. In: Kevles DJ, Hood L, editors. The code of codes: scientific and social issues in the Human Genome Project. Cambridge: Harvard University Press, 1992:211-43.